文献速递胸部肿瘤放疗姑息放疗与转移瘤放疗物理与技术

三维适形放疗降低肺癌姑息放疗毒性的多中心临床试验

Cancer Trials Ireland (ICORG) 06-34: A multi-centre clinical trial using three-dimensional conformal radiation therapy to reduce the toxicity of palliative radiation for lung cancer.
PubMed 文献 · Radiother Oncol · 2018-03-13

结果显示治疗期间14%患者出现2级食管炎或吞咽困难,1个月随访时无2级及以上食管炎或吞咽困难,生活质量较基线改善。

要点

  • 三维适形姑息放疗治疗期间2级食管炎或吞咽困难发生率为14%。
  • 放疗后1个月随访无2级及以上食管炎或吞咽困难报告。
  • 1个月随访时患者整体生活质量较基线改善,仅报告稍感疲劳。

核心结论

  • 三维适形放疗可为肺癌姑息治疗患者提供较低的食管毒性发生率,同时获得可接受的症状控制率。

研究设计与样本

  • 采用三维适形技术,标准化剂量方案为39 Gy分13次、20 Gy分5次或17 Gy分2次,治疗计划力求最小化食管剂量。

主要发现

  • 治疗期间5例(14%)患者出现2级食管炎或吞咽困难或两者兼有,另有2例在2周随访时出现这些副作用。
  • 放疗后1个月随访时无2级及以上食管炎或吞咽困难报告。
  • 22例患者可评估晚期毒性,其中5例报告食管炎或吞咽困难(1例3级吞咽困难,2例2级食管炎,其中1例同时有2级吞咽困难)。
  • 20例患者有基线和1个月随访的生活质量数据,1个月时短距离行走困难稍减轻、呼吸困难减轻、疲乏感减轻、食欲改善、整体生活质量优于基线,但报告稍感疲劳。

临床怎么用

  • 对症状性局部晚期或转移性非小细胞肺癌行姑息放疗时,可采用三维适形技术以降低食管毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TITLE: Cancer Trials Ireland (ICORG) 06-34: A multi-centre clinical trial using three-dimensional conformal radiation therapy to reduce the toxicity of palliative radiation for lung cancer. NCT01176487. BACKGROUND & PURPOSE: Trials of radiation therapy for the palliation of intra-thoracic symptoms from locally advanced non-small cell lung cancer (NSCLC) have concentrated on optimising fractionation and dose schedules. In these trials, the rates of oesophagitis induced by this "palliative" therapy have been unacceptably high. In contrast, this non-randomised, single-arm trial was designed to assess if more technically advanced treatment techniques would result in equivalent symptom relief and reduce the side-effect of symptomatic oesophagitis. MATERIALS & METHODS: Thirty-five evaluable patients with symptomatic locally advanced or metastatic NSCLC were treated using a three-dimensional conformal technique (3-DCRT) and standardised dose regimens of 39 Gy in 13 fractions, 20 Gy in 5 fractions or 17 Gy in 2 fractions. Treatment plans sought to minimise oesophageal dose. Oesophagitis was recorded during treatment, at two weeks, one month and three months following radiation therapy and 3-6 monthly thereafter. Mean dose to the irradiated oesophagus was calculated for all treatment plans. RESULTS: Five patients (14%) had experienced grade 2 oesophagitis or dysphagia or both during treatment and 2 other patients had these side effects at the 2-week follow-up. At follow-up of one month after therapy, there was no grade two or higher oesophagitis or dysphagia reported. 22 patients were eligible for assessment of late toxicity. Five of these patients reported oesophagitis or dysphagia (one had grade 3 dysphagia, two had grade 2 oesophagitis, one of whom also had grade 2 dysphagia). Quality of Life (QoL) data at baseline and at 1-month follow up were available for 20 patients. At 1-month post radiation therapy, these patients had slightly less trouble taking a short walk, less shortness of breath, did not feel as weak, had better appetite and generally had a better overall quality of life than they did at baseline. They did report being slightly more tired. CONCLUSIONS: This trial is the first of its kind showing that 3-DCRT provides patients with lower rates of oesophageal toxicity whilst yielding acceptable rates of symptom control. (Sponsored by Cancer Trials Ireland (ICORG) Study number 06-34, the Friends of St. Luke's and the St. Luke's Institute of Cancer Research.).

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. McDermott RL, Armstrong JG, Thirion P, et al. Cancer Trials Ireland (ICORG) 06-34: A multi-centre clinical trial using three-dimensional conformal radiation therapy to reduce the toxicity of palliative radiation for lung cancer. Radiother Oncol. 2018. PMID: 29548561. doi:10.1016/j.radonc.2018.02.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。